Home - Products - Others - Other Targets - 8-O-Acetylharpagide

8-O-Acetylharpagide

CAS No. 6926-14-3

8-O-Acetylharpagide( —— )

Catalog No. M19005 CAS No. 6926-14-3

8-O-Acetylharpagide has a biological activity on isolated smooth muscle preparations from guinea pig.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	97	In Stock
10MG	165	In Stock
25MG	294	In Stock
100MG	Get Quote	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

8-O-Acetylharpagide
Note

Research use only, not for human use.
Brief Description

8-O-Acetylharpagide has a biological activity on isolated smooth muscle preparations from guinea pig.
Description

8-O-Acetylharpagide has anti-inflammatory activity. 8-O-Acetylharpagide has antibacteria and antiviral activities. 8-O-Acetylharpagide has a biological activity on isolated smooth muscle preparations from guinea pig.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

antibacterial
Research Area

Infection|Inflammation/Immunology
Indication

——

Chemical Information

CAS Number

6926-14-3
Formula Weight

406.38
Molecular Formula

C17H26O11
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 25 mg/mL (61.52 mM)
SMILES

CC(=O)OC1(CC(C2(C1C(OC=C2)OC3C(C(C(C(O3)CO)O)O)O)O)O)C
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

Beta-Hederin

Beta-Hederin has apoptotic effect on breast cancer cells, it could be a promising candidate for chemotherapy of breast cancer.
Dehydro Nifedipine

Dehydro Nifedipine (BAY-b 4759) is the main metabolite of nifedipine in human plasma.
Siplizumab

Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2, selectively depleting effector memory T cells and promoting the relative expansion of alloreactive regulatory T cells in vitro. Siplizumab can be used to treat plaque psoriasis.

Sign In Join Free